Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

of IPF-related deaths during treatment was also lower among patients treated with pirfenidone. IPF-related deaths occurred during the treatment period in 4.1% of patients in the pirfenidone group and 8.1% of patients in the placebo group in CAPACITY 1. IPF-related deaths occurred during the treatment period in 2.9% of pirfenidone group and 6.3% of patients in the placebo group in CAPACITY 2.

Treatment Discontinuation due to Adverse Events

Pirfenidone was safe and generally well tolerated. Relatively few adverse events resulted in treatment discontinuations. The percentage of patients in the 2403 mg pirfenidone and placebo groups across both CAPACITY studies who discontinued treatment (pirfenidone/placebo) due to various adverse events were as follows: IPF (2.9/2.6); rash (1.4/0); nausea (1.4/0); bladder cancer (0.9/0); photosensitivity reaction (0.9/0.3); respiratory failure (0.9/0.3) and weight decrease (0.6/0).

Laboratory Tests

A total of 30 laboratory tests were regularly performed in CAPACITY. The incidence of grade 3/4 laboratory abnormalities was similar between treatment groups in both studies. In six of the tests, Grade 3/4 abnormalities were noted slightly more frequently in patients treated with pirfenidone (phosphate elevation, hyponatremia, lymphopenia, ALT elevation, AST elevation and cholesterol elevation). Of these laboratory abnormalities in pirfenidone patients, all but one case each of hyponatremia and lymphopenia were Grade 3. In four of the laboratory tests, Grade 3/4 abnormalities were noted slightly more frequently in patients treated with placebo (urate elevation, hyperkalemia, amylase elevation and creatine kinase elevation). Both the incidence of grade 3/4 lab abnormalities and the differences observed between treatment groups on all tests were small.

Regarding the overall safety results, Dr. du Bois commented, "The safety and tolerabilit
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... SAN FRANCISCO , Aug. 3, 2015  Sage ... generation of portable laboratory-quality cannabis potency measurement systems, announced ... PAC Bay Area Cruise Fundraiser. A limited number of ... the festivities and help a great cause while enjoying ... a scenic cruise around the San Francisco Bay at ...
(Date:8/3/2015)... -- Depomed, Inc. (NASDAQ: DEPO ) ("Depomed" or the ... HZNP ) ("Horizon") announcement that it intends to request ... record date to determine the shareholders eligible to request ... will review the request when it is received. Provided ... information required under Depomed,s bylaws, the Depomed Board will, ...
(Date:8/3/2015)... NEW YORK , August 3, 2015 /PRNewswire/ ... report published by Persistence Market Research "Global Market ... to Witness Highest Growth by 2022", ... at US$15 Bn by the end of 2015 and ... 6.8% from 2015 to 2022, to account for ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4
... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2012 first quarter financial results. (Logo:   ... be broadcast live over the internet on Wednesday, November 9, ... and may be accessed by visiting the Company,s website at ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... were published in Obesity, the peer-reviewed journal of The ... the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 ... addition to average weight loss of 14.4% of initial body weight ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Financial Results Conference Call and Webcast 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 3Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 4Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 5Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 6
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... Back Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can Last ... pain in patients. According to the report, the new study showed that harvesting stem ...
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has completed ... The acquisition includes all of IBAM NA’s cyclotron sites and research and development facilities. ... regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” said ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... insurance brokerage firm, announced today that Joe Williams has joined its growing California ... and delivering HUB's differentiated service model to his clients. Mr. Williams will be ...
(Date:8/3/2015)... ... 03, 2015 , ... Cambia Health Solutions has promoted Scott ... company’s Medicare and Federal Employee Programs (FEP) lines of business. , Government ... members. In this role, Scott is responsible for overseeing the growth, finance and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Examination ... and investigative services, has introduced a new logo and comprehensive brand strategy ... improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. Improved ...
Breaking Medicine News(10 mins):Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... Mich., Dec. 10 GeneGo, Inc., a leading,provider of ... analysis ,today announced that A*STAR,s Singapore Immunology Network (SIgN) ... researchers will have access,to GeneGo,s MetaCore, training and advanced ... for all SIgN researchers. , ...
... in one resource the necessary information to make an informed decision when ... ... Lyndhurst, NJ (PRWEB) December 10, 2008 -- From picking a great pediatrician ... is), navigating the medical landscape can be a daunting task, especially if ...
... www.patheon.com , , ... Patheon (TSX:PTI), a global provider of drug development and ... to announce the opening of its new U.S. headquarters ... Triangle Park (RTP), North Carolina. , Established ...
... Trials and the Company,s Other Clinical Programs All Advanced During the ... Validation Achieved for Bavituximab and Peregrine,s Anti-PS Anti-Viral Platform in Nature ... Company Enters into Loan Agreement for Up to $10 Million in ... Dec. 10 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) ...
... , , TUCSON, Ariz., Dec. ... PRSC ) today announced that its Board of Directors has ... shareholders will receive rights to purchase shares of the Company,s ... , "In this period of unprecedented market volatility ...
... Consumers Advised to Secure Long Term Care Insurance While They,re ... KIRKLAND, Wash., Dec. 10 If you,ve put ... off a bit longer, anticipating the new administration,s health plan? ... Board of LTC Financial Partners LLC (LTCFP), one of the ...
Cached Medicine News:Health News:A*STAR's Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia 2Health News:Vitals Launches Free eBook to Help Consumers Find "Dr. Right" 2Health News:Patheon Opens New U.S. Headquarters and Analytical Laboratory Facility in Research Triangle Park, NC 2Health News:Patheon Opens New U.S. Headquarters and Analytical Laboratory Facility in Research Triangle Park, NC 3Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 2Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 3Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 4Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 5Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 6Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 7Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 8Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 9Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 10Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 11Health News:Providence Service Corporation Adopts Shareholder Rights Plan 2Health News:Providence Service Corporation Adopts Shareholder Rights Plan 3Health News:Obama Health Plan Not Likely to Embrace Long Term Care, Industry Leader Says 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: